Publications
Detailed Information
Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Wonjae | - |
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Park, Jin Joo | - |
dc.contributor.author | Yoon, Chang-Hwan | - |
dc.contributor.author | Cho, Young-Seok | - |
dc.contributor.author | Youn, Tae-Jin | - |
dc.contributor.author | Chae, In-Ho | - |
dc.date.accessioned | 2019-03-06T04:42:57Z | - |
dc.date.available | 2019-03-06T13:45:23Z | - |
dc.date.issued | 2018-10-22 | - |
dc.identifier.citation | BMC Cardiovascular Disorders, 18(1):201 | ko_KR |
dc.identifier.issn | 1471-2261 | - |
dc.identifier.uri | https://hdl.handle.net/10371/146855 | - |
dc.description.abstract | Background
We conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR). Methods Patients with an HPR, defined as P2Y12 reaction unit (PRU) > 230, were randomly assigned to group A (tirofiban treatment, n = 30) or C1 (n = 30) and patients without an HPR to C2 (n = 78). Periprocedural myocardial damage was assessed using the area under the curve (AUC) of serial cardiac enzyme levels from the time of the procedure to post-36h. Periprocedural myonecrosis incidence was evaluated. Results The troponin I AUC was not different between the groups (197.2 [41.5395.7], 37.9 [8.9313.9], 121.3 [43.7481.8] h∙ng/mL; p = 0.088). The results did not change when the baseline levels were adjusted (365.3 [279.5, 451.1], 293.0 [207.1, 379.0], and 298.0 [244.7, 351.3] h∙ng/mL; p = 0.487). The rate of periprocedural myonecrosis was also not different between the groups (53.0% vs. 50.0% vs. 33.3%, p = 0.092). The CK-MB isoenzyme analysis showed similar results. No difference in complications was noted. Conclusion Additional tirofiban administration was not beneficial to patients with NSTE-ACS even with an HPR. Trial registration Clinical trial no. NCT03114995, registered 11 April, 2017, retrospectively. | ko_KR |
dc.description.sponsorship | This clinical trial was supported by Handok Phamaceutical Ltd. The role of funding was primarily in the collection of the data and not in writing the manuscript. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Glycoprotein IIb/IIIa inhibitor | ko_KR |
dc.subject | Tailored antiplatelet treatment | ko_KR |
dc.subject | Periprocedural myonecrosis | ko_KR |
dc.subject | High residual platelet activity | ko_KR |
dc.title | Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이원재 | - |
dc.contributor.AlternativeAuthor | 서정원 | - |
dc.contributor.AlternativeAuthor | 박진주 | - |
dc.contributor.AlternativeAuthor | 윤창환 | - |
dc.contributor.AlternativeAuthor | 조영석 | - |
dc.contributor.AlternativeAuthor | 채인호 | - |
dc.identifier.doi | 10.1186/s12872-018-0938-6 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2018-10-28T15:08:16Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.